Aryx Therapeutics Current Valuation vs. Book Value Per Share
| ARYXDelisted Stock | USD 0.0005 0.00 0.00% |
For Aryx Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Aryx Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Aryx Therapeutics I utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Aryx Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Aryx Therapeutics I over time as well as its relative position and ranking within its peers.
Aryx |
Aryx Therapeutics Book Value Per Share vs. Current Valuation Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Aryx Therapeutics's current stock value. Our valuation model uses many indicators to compare Aryx Therapeutics value to that of its competitors to determine the firm's financial worth. Aryx Therapeutics I is rated fifth in current valuation category among its peers. It is rated fourth in book value per share category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Aryx Therapeutics by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Aryx Therapeutics' Pink Sheet. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Aryx Current Valuation vs. Competition
Aryx Therapeutics I is rated fifth in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Health Care industry is presently estimated at about 3.83 Billion. Aryx Therapeutics adds roughly 237,580 in current valuation claiming only tiny portion of equities under Health Care industry.
Aryx Book Value Per Share vs. Current Valuation
Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Aryx Therapeutics |
| = | 237.58 K |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.
Aryx Therapeutics |
| = | (0.23) X |
The naive approach to look at Book Value per Share is to compare it to current stock price. If Book Value per Share is higher than the currently traded stock price, the company can be considered undervalued. However, investors must be aware that conventional calculation of Book Value does not include intangible assets such as goodwill, intellectual property, trademarks or brands and may not be an appropriate measure for many firms.
Aryx Book Value Per Share Comparison
Aryx Therapeutics is currently under evaluation in book value per share category among its peers.
Aryx Therapeutics Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Aryx Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Aryx Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Aryx Therapeutics' change in net profit over the period of time. It can combine multiple indicators of Aryx Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
ARYx Therapeutics, Inc. discovers and develops novel therapies for large, chronic, and oral markets. ARYx Therapeutics, Inc. was founded in 1997 and is based in Fremont, California. ARYX THERAPEUTICS operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on PNK Exchange. It employs 56 people.
Aryx Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Aryx Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Aryx Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Aryx Therapeutics' important profitability drivers and their relationship over time.
Learn to be your own money manager
Our tools can tell you how much better you can do entering a position in Aryx Therapeutics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Price Transformation Now
Price TransformationUse Price Transformation models to analyze the depth of different equity instruments across global markets |
| All Next | Launch Module |
Use Investing Themes to Complement your Aryx Therapeutics position
In addition to having Aryx Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Developed Markets Basket ETFs Thematic Idea Now
Developed Markets Basket ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Developed Markets Basket ETFs theme has 24 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Developed Markets Basket ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Other Consideration for investing in Aryx Pink Sheet
If you are still planning to invest in Aryx Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Aryx Therapeutics' history and understand the potential risks before investing.
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing |